HI 164

Drug Profile

HI 164

Alternative Names: HI-164N; HI-164OV

Latest Information Update: 24 Jul 2015

Price : $50

At a glance

  • Originator Hunter Immunology
  • Developer Mariposa Health Limited
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Discontinued Bronchitis; Otitis media; Sinusitis

Most Recent Events

  • 24 Jul 2015 Phase-II development for Chronic obstructive pulmonary disease (prevention of exacerbation) is ongoing in Australia
  • 30 Jun 2014 Mariposa Health Limited acquires Hunter Immunology
  • 29 Jun 2012 Final efficacy data from a phase IIb trial in Chronic obstructive pulmonary disease released by Bioxyne
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top